Zentalis Pharmaceuticals (ZNTL) Restructuring Costs (2025)

Zentalis Pharmaceuticals (ZNTL) posted quarterly Restructuring Costs of $7.8 million for Q1 2025.

Zentalis Pharmaceuticals (ZNTL) Restructuring Costs (2025) Analysis & Trends

Zentalis Pharmaceuticals' Restructuring Costs history runs 1 years deep, the most recent figure standing at $7.8 million for Q1 2025.

In Q1 2025, Restructuring Costs changed N/A year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $7.8 million (changed N/A YoY), while the FY2025 annual figure was $7.8 million, changed N/A from the prior year.
Restructuring Costs for Q1 2025 stood at $7.8 million.
The five-year high for Restructuring Costs was $7.8 million in Q1 2025, with the low at $7.8 million in Q1 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Zentalis Pharmaceuticals	255.14 Mn	255.14 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2025	7.80 Mn